INDiGO Select
An integrated candidate de-risking package that helps early-stage teams choose the right molecule to take forward, and reach IND faster. It brings the critical early developability, safety and DMPK questions into one coordinated workstream, so you can make a confident go/no-go decision before committing to a full IND-enabling programme.
Receive your quote directly from the manufacturer.
INDiGO Select is the lower-commitment entry point to Evotec's integrated drug development. It front-loads the studies that most often de-risk an early candidate, developability, early safety and DMPK, under a single accountable team, giving you an evidence-based view of whether your molecule is ready to progress and a clear plan to IND.
Because it runs on the same integrated platform as our full INDiGO programme, the work flows seamlessly from candidate selection into IND-enabling studies and onward toward clinical readiness, with no hand-offs and one team accountable end to end.
Key benefits:
- Early, evidence-based go/no-go on your lead candidate
- Developability, early safety and DMPK in one coordinated workstream
- A single accountable team from candidate selection to IND
- Built to accelerate the path to IND and reduce late-stage attrition
- Western, IP-secure delivery with the resilience of a single partner
Typical applications:
- Early-stage biotech selecting between lead candidates
- Teams preparing a molecule for a full IND-enabling programme
- Programmes needing to de-risk before major preclinical investment
Structuring analytical data for the future of regulatory submission with INDiGO
Bringing a small molecule from candidate nomination to clinical development is often a fragmented process, with handoffs between teams creating delays, increasing costs, and introducing risk. At the same time, up to 90% of drug candidates fail before market approval, highlighting the need for smarter strategies to identify and address potential roadblocks as early as possible.
This resource explores how Evotec’s INDiGO® and INDiGO-Select platforms streamline development through an integrated, science-driven approach. Discover how INDiGO-Select reduces IND-enabling attrition from 30–40% to 5%, and learn how early de-risking can accelerate timelines, strengthen confidence, and improve the chances of clinical success.
Product Overview
Links
Featured products
Request Quote for All ProductsINDiGO
EvotecAn integrated candidate de-risking package that helps early-stage teams choose the right molecule to take forward, and reach IND faster. It brings the critical early developability, safety and DMPK questions into one coordinated workstream, so you can make a confident go/no-go decision before committing to a full IND-enabling programme.